OM PHARMA enters new partnership agreement for Uro-Vaxom® in Russia & CIS with Astellas Pharma

Geneva, February 8th, 2010

OM PHARMA is proud to announce the signature of an important new partnership agreement with the multinational Japanese company Astellas Pharma, for the distribution and promotion of Uro-Vaxom® in the Russian and CIS markets.

The partnership will give OM PHARMA access to Astellas Pharma in Russia a leading and strong performing company particularly in the field of Urology.

Uro-Vaxom®, OM PHARMA’s biotechnology product indicated for the prevention and treatment of recurrent urinary tract infections, is the first and leading immunostimulant product in this therapeutic area. This oral medication acts by modulating the body’s own immune defences against pathogenic micro-organisms.

Uro-Vaxom® is already successfully marketed in over 30 countries and is supported by high standard clinical trials and documented therapeutic benefits.